- Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside KeytrudaThe Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Par…BioSpace · 9d ago↗ source
- Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechsWhen Axiom's stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn neurological diseases this week, the biotech's leadership saw a broader validation for th…Fierce Biotech · 9d ago↗ source
- BIO San Diego 2026 Executive InterviewsEvery year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ecosystem.